TG Therapeutics, Inc.
https://www.tgtherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TG Therapeutics, Inc.
Lilly Looks To Take POINT On Emerging Cancer Radiopharmaceutical Space
Lilly has agreed to pay $1.4bn to acquire Point even though the company’s two lead candidates are out-licensed to Lantheus. The deal looks like an early-stage play to build a strong position in an emerging field.
TG Therapeutics Briumvi Deal Fails To Impress The Market
Linking up with Germany’s Neuraxpharm to sell the multiple sclerosis drug Briumvi in Europe and elsewhere has gone down badly with investors but the bashing that TG Therapeutics’ shares has taken seems excessive.
Roche Touts 10-Minute Ocrevus Benefits For MS
A subcutaneous version of Ocrevus is as effective as the intravenous form of Roche's biggest seller, and could boost access of the multiple sclerosis drug where access to intravenous clinics is problematic.
Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else
Almost 80% of novel agent submissions from the biggest companies were approved in recent years, compared with a 60% approval rate for the rest of the industry, according to a recent analysis of FDA approval decisions since 2021.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Ariston Pharmaceuticals, Inc.
- Atlantic Pharmaceuticals, Inc.
- Atlantic Technology Ventures, Inc.
- Manhattan Pharmaceuticals, Inc.
- Manhattan Research Development, Inc.
- Tarpan Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice